Alembic Pharmaceuticals Limited (NSE:APLLTD) announced on 28 July 2026 that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Prucalopride Tablets in 1 mg and 2 mg strengths. The product is therapeutically equivalent to Motegrity Tablets and targets the chronic idiopathic constipation market, which carries an estimated market size of US$100 million for the twelve-month period ending March 2026 according to IQVIA data.
Key Highlights
- Alembic Pharmaceuticals received final USFDA approval for Prucalopride Tablets, 1 mg and 2 mg, on 28 July 2026.
- The approved product is therapeutically equivalent to Takeda Pharmaceuticals' Motegrity Tablets and is indicated for treatment of chronic idiopathic constipation in adults.
- Prucalopride tablets are serotonin-4 receptor agonists with an estimated US market size of US$100 million for the twelve-month period ending March 2026.
- The approval brings Alembic's cumulative USFDA ANDA approvals to 245, comprising 225 final approvals and 20 tentative approvals.
- Alembic manufactures generic pharmaceutical products at USFDA-approved facilities and markets branded generics in India through a field force exceeding 5,500 personnel.
About the Company
Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company headquartered in Vadodara, India. Since its establishment in 1907, the company has manufactured and marketed generic pharmaceutical products globally. The company operates state-of-the-art research and manufacturing facilities approved by regulatory authorities in developed countries, including the USFDA. In the Indian market, Alembic is a leading player in branded generics, with a field force exceeding 5,500 personnel marketing its brands to doctors and patients. The company is listed on both the NSE (ticker: APLLTD) and BSE (scrip code: 533573) and maintains a significant presence in the global generic pharmaceutical sector with cumulative USFDA ANDA approvals totalling 245.
Announcement in Detail
Alembic Pharmaceuticals announced the receipt of final USFDA approval for Prucalopride Tablets, 1 mg and 2 mg, through its Abbreviated New Drug Application (ANDA). The approval was filed to the exchanges on 28 July 2026. Prucalopride tablets are serotonin-4 receptor agonists, a therapeutic class indicated for the treatment of chronic idiopathic constipation in adults. The approved product is therapeutically equivalent to the reference listed drug Motegrity Tablets, 1 mg and 2 mg, manufactured by Takeda Pharmaceuticals USA Inc.
According to IQVIA market data, Prucalopride tablets in these strengths carry an estimated market size of US$100 million for the twelve-month period ending March 2026. This approval represents Alembic's incremental addition to its global ANDA portfolio. As of the announcement date, the company holds a cumulative total of 245 ANDA approvals from the USFDA, of which 225 are final approvals and 20 are tentative approvals. The company's manufacturing facilities are approved by regulatory authorities of multiple developed countries, including the USFDA, enabling the company to supply generic products to international markets.
Impact on Investors
The USFDA approval for Prucalopride Tablets expands Alembic's generic product portfolio and provides the company with access to an estimated US$100 million market opportunity in chronic idiopathic constipation therapeutics. Investors will note that USFDA approvals are material milestones for Indian generic pharmaceutical companies, as they enable market entry into the highly regulated United States pharmaceutical market and contribute to revenue diversification and growth. The filing shows that Alembic has now accumulated 245 total ANDA approvals, indicating sustained regulatory progress and operational execution in its US-focused generic business.
The therapeutic equivalence designation means the approved product meets bioavailability and bioequivalence standards, positioning Alembic to compete with the branded reference product in the US market. Shareholders will observe that continued USFDA approvals strengthen the company's market presence in oncology, gastroenterology, and other therapeutic segments. However, investors should note that actual commercial performance in the US market depends on factors including manufacturing scale-up, pricing, competition from other approved generics, and distribution partnerships, none of which are addressed in this announcement. The disclosure does not provide timing for commercial launch or revenue contribution expectations.
Sector / Market Context
The Indian generic pharmaceutical sector has maintained steady regulatory approvals from global authorities, particularly the USFDA, which remains the primary gateway for Indian companies to access the large-scale US market. The US generic pharmaceutical market continues to represent a significant revenue source for Indian manufacturers due to cost competitiveness and established regulatory approvals. USFDA approvals for new molecules or new formulations are tracked closely by investors as indicators of pipeline productivity and commercial pipeline depth.
Chronic idiopathic constipation is a gastrointestinal therapeutic area with established clinical demand in developed markets. Prucalopride, as a serotonin-4 receptor agonist, competes within a defined therapeutic class. The US$100 million market size disclosed for the twelve-month period ending March 2026 reflects the addressable opportunity for approved generic manufacturers in this segment. For Alembic, this approval reinforces its position as a diversified generic manufacturer with approvals across multiple therapeutic categories and regulatory jurisdictions.